UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

June 2, 2021

Date of Report (Date of earliest event reported)

Immune Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code 888-613-8802

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Smaller Reporting Company [X]

Indicate by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act: Yes [  ] No [X]

Item 8.01. Other Events.

On May 25, 2021, Immune Therapeutics, Inc. (the “Company”) entered into a non-binding Letter of Intent with certain of the Company’s existing investors. Readers should refer to the Letter of Intent filed as an exhibit to this Form 8-K to review all of the terms and conditions of the Letter of Intent. The primary terms of this non-binding Letter of Intent are:

- The investors will lend a minimum of $700,000 and a maximum of $1,500,000 to the Company in exchange for non-convertible promissory notes bearing interest at 5%.

- Each lender will sign a 12-month lock-up agreement.

In connection with the transactions above, certain amounts owed to former employees, current management and directors, and other accounts payable will be renegotiated. Closing of the transactions contemplated by the Letter of Intent are subject to a number of conditions being satisfied, including the completion of due diligence.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.